Eton Pharmaceuticals (ETON) Equity Average (2019 - 2025)
Historic Equity Average for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $23.5 million.
- Eton Pharmaceuticals' Equity Average rose 5992.6% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 5992.6%. This contributed to the annual value of $20.0 million for FY2024, which is 3974.79% up from last year.
- According to the latest figures from Q3 2025, Eton Pharmaceuticals' Equity Average is $23.5 million, which was up 5992.6% from $24.2 million recorded in Q2 2025.
- Eton Pharmaceuticals' 5-year Equity Average high stood at $24.4 million for Q1 2025, and its period low was $12.1 million during Q4 2022.
- Moreover, its 5-year median value for Equity Average was $16.2 million (2023), whereas its average is $17.1 million.
- In the last 5 years, Eton Pharmaceuticals' Equity Average skyrocketed by 33230.79% in 2021 and then tumbled by 3704.33% in 2022.
- Eton Pharmaceuticals' Equity Average (Quarter) stood at $16.6 million in 2021, then fell by 27.13% to $12.1 million in 2022, then skyrocketed by 33.43% to $16.2 million in 2023, then grew by 24.84% to $20.2 million in 2024, then grew by 16.53% to $23.5 million in 2025.
- Its last three reported values are $23.5 million in Q3 2025, $24.2 million for Q2 2025, and $24.4 million during Q1 2025.